Sign in to view Jonathan’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
United States
Contact Info
Sign in to view Jonathan’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
3K followers
500+ connections
Sign in to view Jonathan’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
View mutual connections with Jonathan
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
View mutual connections with Jonathan
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Sign in to view Jonathan’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Experience & Education
-
Function Health
**-*******, ***
-
****** **
**-*******
-
****-********
********
-
********** ** ******** - ****** *. ***** ****** ** ********
*.*. *******, ****************, ******** *******
View Jonathan’s full experience
See their title, tenure and more.
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
Licenses & Certifications
View Jonathan’s full profile
Sign in
Stay updated on your professional world
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Other similar profiles
-
Ed Sim
Miami, FLConnect -
Cindy Padnos
San Francisco Bay AreaConnect -
Gaurav Jain
San Francisco, CAConnect -
Matthew Jacobson
San Francisco Bay AreaConnect -
Jonathon Triest
Detroit, MIConnect -
John Xie
San Francisco, CAConnect -
Scott Roberts
Bolinas, CAConnect -
Rahul Vohra
San Francisco, CAConnect -
Bobby Brannigan
San Diego, CAConnect -
Nick Raushenbush
United StatesConnect -
Ken Elefant
Palo Alto, CAConnect -
Matt Garratt
Menlo Park, CAConnect -
Ben Taft
Los Angeles, CAConnect -
Eliot Durbin
United StatesConnect -
Chase Norlin
Phoenix, AZConnect -
Nick Cromydas
Greater Chicago AreaConnect -
Terrence Rohan
San Francisco, CAConnect -
Greg Neufeld
Delray Beach, FLConnect -
Matt Mireles
San Francisco Bay AreaConnect -
Nitin Pachisia
San Francisco Bay AreaConnect
Explore more posts
-
Jason Kirby
Looking beyond #VC funding for your #startup? Aakash Shah of Wyndly (YC W21) reveals how he built a multi-million dollar #healthtech company using creative capital strategies. Learn how he leveraged Y Combinator's network and alternative funding methods to revolutionize allergy treatment. In case you missed it, you can watch the #FundraisingDemystified #podcast here: https://lnkd.in/eZT63YS4
52 Comments -
Jeffrey Paine
What does it take to raise capital for SaaS companies now according to Jason Lemkin (SaaStr) Key Takeaway 1: The current venture capital landscape is experiencing significant changes, particularly driven by the rise of AI. Investors are increasingly focused on finding "decacorns" (companies valued at over $10 billion) in the AI space, as traditional software companies are no longer seen as sufficient for generating massive returns. > Agree, its a generational new sector that will change the world in the short to medium term Key Takeaway 2: There's a growing trend of large investments in AI companies, even those without established revenue or customers. This is exemplified by Elon Musk's new AI company raising $6 billion and OpenAI's rapid growth. Investors are making high-risk bets on potential AI breakthroughs, driven by the need for outsized returns. Key Takeaway 3: Established venture capital firms and investors are pivoting their focus towards AI. SoftBank is raising a $9 billion fund solely for AI investments, while prominent hedge fund manager Steve Cohen has restructured his venture fund to concentrate exclusively on AI opportunities. > This signals huge momentum of capital, a good but wary signal. Overall a very good signal. Key Takeaway 4: The AI investment trend is not without skepticism. There's recognition that some companies may be falsely claiming AI capabilities to attract funding. However, real-world applications and significant deals, such as Palantir's $480 million AI contract with the US Army, demonstrate the tangible potential of AI technologies. > As with any new exploding trend, be wary always. Key Takeaway 5: The venture capital industry is under pressure to find and invest in potential decacorns, as traditional software companies, even successful ones, are no longer considered sufficient for generating the massive returns required by large VC funds. This shift is causing stress and driving the focus towards high-potential AI startups. > Power law distribution and math doesn't lie (that much). https://lnkd.in/gHe8tW2E
18 -
Jenn Summe
A little late, even though this process started in July.... Excited to share our latest investment in Heads Together Health!! We met Steve DeVrieze in October last year, and we think they are poised for impressive growth! Read more here: https://lnkd.in/ecYcqqkn #earlystagestartup #earlystageinvesting #VCinvestment #ncstartups #nctechstartups
19 -
Jimmy Frischling
Last month, Uncork Capital celebrated its 20th anniversary with a jubilant gathering attended by 420 guests, marking two decades of success in the venture capital realm. Over the years, the firm, alongside industry peers like First Round Capital and Felicis, has witnessed remarkable growth, now managing billions of dollars in assets. This expansion reflects the flourishing landscape of venture capital, with the industry experiencing exponential growth in investment. Moreover, positive shifts in VC norms, such as the evolving attitudes towards board seats, underscore a commitment to providing tailored support to startups, enhancing their growth prospects. Amidst discussions surrounding sectors like AI, optimism prevails, emphasizing a steadfast dedication to investing in innovative ventures with lasting impact. Read More Here: https://lnkd.in/efN6-Spd Branded Hospitality Ventures Jeff Clavier Susan Liu Ashley Cravens Tripp Jones Sarah Du Andy McLoughlin Amy Saper #innovation #technology #management #venturecapital #startup
6 -
Erik Bruckner
The state of venture capital is wild right now. We are witnessing a surge of innovation across the spectrum: - Funds merging - VC doing PE - PE doing VC - Secondary funds - Buyout funds - Spin-out funds - Debt funds - Continuation funds - Infrastructure funds - GP turnover - Hard Tech surging - Family Office uptick
608 Comments -
Garnet S. Heraman
One of my proudest moments as an investor occurred today as Alaffia Health announced its series A because it shows how the Aperture® Venture Capital vision of multi-level, multi-generational #impactinvesting is succeeding in the marketplace. Here’s the model in its most basic form : ✅As diverse fund managers with meaningful capital to allocate, we are changing the VC landscape every day just by doing our day jobs. ✅As Black/Brown investors with ~40 years experience collectively, Aperture GPs have access to talent /excellence that others do not, so our portfolio *organically* is more inclusive by race, gender and geography even while optimizing for financial outcomes (all about the alpha). ✅Our most successful portco’s are using financial #innovation to solve market problems that impact underrepresented demographics and underserved communities. Alaffia Health is a shining example of the impact portion of our overall fund thesis, and we couldn’t be prouder of TJ Ademiluyi and Adun Akanni, MPH, PMP - the dynamic brother-sister founder duo whose vision we have steadfastly supported on their journey. Congratulations to TJ and Adun from William Crowder and myself, as well as the whole Aperture team- Marjorie King Philip McKenzie Yves Louis-Jacques Tanvi Lal Michelle Dhansinghani Lisha Bell Katie Kelly Amy Chung Cindy Chong, CFA Brian Fernandes-Halloran Monroe France Jayden Pantel Darren Herman Evan Wladis Neal Triplett Thomas Scriven Peter Ammon Irina Bit-Babik Tim Milanich Rob Rahbari
3818 Comments -
JJ Fliegelman
I'm excited to be leading my third YC demo day fund for the S24 batch! I've been involved with YC since 2015, first going through YC myself, staying closely involved with the community for 7+ years, and culminating in working there as a Visiting Partner, where I invested in over 120 companies and helped them raise over $200M in capital. Over all this time, one thing is clear to me: YC founders are only getting better and better, and YC companies remain the cream of the crop for early stage founders. And it's not because companies come out of YC "fully baked" -- many of the best companies went through Demo Day with no revenue, or even pivoting just a few months afterwards. Yet, over 5% of this batch will likely become unicorns. This batch is appears to be the biggest one since 2021, which will make for the most interesting (and more competitive) cycle in a long time. I have opened this fund up to friends and connections who would like to join me. If you are interested in participating, click the link below for special friends-only terms! https://lnkd.in/eSKEbqQJ
25 -
Surbhi Sarna
The power of three! There are three YC companies that have absolute dream teams consisting of three founders each who happened to announce their existence to the world on the same day. They are working on some of the biggest issues impacting humanity: the creation and education of healthcare providers, agtech/climate, and women’s health. I honestly could not have dreamed up better teams to tackle these massive problems. Synaptiq (YC 23) was started by three friends who have known one another since elementary school: a UCSF-trained physician, an engineer from Square, and an all-star designer. The physician dropped out of Stanford neurosurgery, the hardest residency program to get into in the country, after scoring in the 100th percentile on the board exam and realizing he could use AI to bring his studying methods to other physicians and healthcare workers. Now they have growing revenue and are on track to launch at almost every medical school in the country. Feanix Biotech (YC 23) was initially started by two geneticists who grew up on dairy farms. They came up with new genetic tests for cows and had skyrocketing revenue but realized that the farmers they were working with could make even better breeding decisions. That’s when they met their third co-founder, an MIT/Google ML engineer who was already working on agtech software of her own. Together, they’re now developing the world’s first software + diagnostic platform for agriculture. Simbie Health (YC 23) was started by a Fulbright fellow physician out of uChicago, an operations leader from Carrot Fertility, and a software engineer from Princeton. They’re working on women’s health, creating software that enables women’s health practitioners to start their own, virtual-first practices. Yes, more women’s health, please! Congratulations on your launch! Ryan Phelps, MD, Jacob Caccamo, Kevin Bastoul; Mitchell Angove, Tom Bishop, Meia Alsup; Natalia Neha Khosla, MD, Rachel O'Driscoll, and Natalia Perina.
22930 Comments -
🚀👨🏾💻Faraz Khan
A new era of deep tech has emerged. First time funds will raise “unheard of” amounts of capital to fuel next gen deep tech startups - producing outsized, superior returns for LP’s compared to the rest. Prudent investors will act on this data and shift investment strategy as LP’s or risk being left behind savvy wealth managers and CIO’s / FO’s who saw this trend begin 4 years ago.
1008 Comments -
Mainak Sarkar
z21 Ventures prioritizes empowering early-stage founders with tailored ecosystem support and mentorship, driving impactful growth. Their founder-first approach and extensive network of industry experts are instrumental in amplifying portfolio success. I confidently refer early-stage founders in my network to z21 Ventures as they possess unparalleled insight into early-stage businesses. #z21ventures #venturecapital #startupgrowth #earlystageinvesting #communitydriven
321 Comment -
Lisa Carmen Wang
A recent monumental milestone for the femtech industry: Flo Health secured $200M in funding, achieving a valuation of over $1 billion as the world's first femtech unicorn. It’s important to acknowledge both the progress and the paradoxes within this achievement. Flo Health, a platform empowering women with vital health insights, was founded by two male cofounders. 🤔 This brings to light a critical discussion about representation and inclusivity in the femtech space. While their contribution is commendable, it underscores the necessity for more female founders and leaders in industries that primarily serve women. As the founder of BAD BITCH EMPIRE dedicated to breaking down barriers for women in business and investing, I see this as a call to action. We need more women at the helm of innovative solutions addressing our unique health needs. It's not just about creating products for women; it's about ensuring these products are driven by the voices and experiences of women themselves. This historic funding round proves that femtech is not only vital but also a lucrative market. Now, let's channel this momentum to elevate more female entrepreneurs, investors, and leaders who can drive the next wave of femtech innovations. #Femtech #WomenInTech #FemaleFounders #InvestInWomen https://lnkd.in/euwbhqVB
494 Comments -
Pablo Castro
In the latest episode of the New Light Ventures podcast, I had an insightful conversation with Matias Serebrinsky, General Partner at PsyMed Ventures, a VC fund investing in groundbreaking brain and mental health technologies. With his diverse background as a founder, AI accelerator lead at NVIDIA, and now investor, Matias shares unique perspectives on the future of mental health innovation. 🌟 3 Key Takeaways: 1. Investing at the Intersection of Psychedelics and AI - PsyMed Ventures is at the forefront of funding companies leveraging psychedelics and artificial intelligence to revolutionize mental health treatment. 2. Founder Empathy from Entrepreneurial Experience - Having co-founded the venture-backed food tech startup CookUnity, Matias deeply understands the founder journey and uses this to support PsyMed's portfolio. 3. Conviction in Contrarian Investments - Matias emphasizes the importance of having strong conviction when investing in emerging areas like psychedelics, even if it means fundraising and sourcing deals is harder initially. "Find your Ikigai. Find the place where your mission and purpose and skills overlap. Because this thing is too hard to do only for clout or money." For anyone interested in the cutting-edge of mental health tech and venture capital, this episode is a must-listen. Matias' insights on the potential of psychedelics, AI, and supporting founders are invaluable for entrepreneurs and investors alike. 🎧 Check out the full episode in the comments and let me know your thoughts!
581 Comment -
Stephanie Campbell
VC funding in healthcare has been more resilient than in other industries. Here are some key takeaways from recent Carta data: 👉 At the priced seed, Series A, and Series B stages, dilution for health startups has noticeably decreased, while dilution for SaaS startups has stayed flat or increased slightly. 👉 In priced seed rounds, median dilution for healthcare companies dipped to 14.2%, compared to 20% for SaaS. 👉 The frequency of bridge rounds surged in the health sector in Q1, jumping to 44.3% from 36.9% in Q4 2023. This is the first significant increase in bridge rounds in healthcare over SaaS since early 2022. 👉 More founder-friendly terms for health startups may result from enduring VC interest since COVID. Healthcare has remained strong through economic turmoil, enabling higher valuations with smaller round sizes. What are the implications? The healthcare sector might see a rise in new ventures due to favorable investment conditions and lower dilution rates. The surge in bridge rounds suggests that certain sectors within healthcare face unique challenges that require interim financing solutions. Founders and investors in the healthcare space- what are your thoughts on this? I’d love to hear from you. If you know a founder innovating in healthcare, tag them in the comments! The Artemis Fund is especially interested in groundbreaking care tech companies. You can check out Carta’s full blog linked in the comments. If you haven’t read our latest blog on care tech, you’ll find that there too. #healthcare #caretech #fundraising
293 Comments -
Michael J. Cunningham, MBA
This week Mikal Ventures brings you a 4-week breakdown of the US capital market with an emphasis on the Mikal verticals. Over the 4-week period ending April 15, just over 900 new companies were added, with 94,109 companies included in the US Health Tech, Med Tech, Fin Tech, AI Tech, and Ed Tech verticals. AI Tech again saw the greatest percentage of growth in new companies and transactions, weighing in at over double the vertical averages for the period. The US Fin Tech vertical again led the way in SEC Filings and news articles. Mikal Ventures publishes these stats on a rolling 4-week basis to provide a perspective on how the verticals and new startups move through time. We hope you find them informative and thought-provoking. VC Investors are always adjusting their "Play Book" with a variety of options for investing. Mikal Ventures is one of those alternatives, offering curated solutions to real world problems. Reach out if you have questions on how we can be of assistance and bookmark https://mikalventures.com/ for additional insights and information.
33 Comments -
Mark Legare
The opioid crisis was a sad hallmark of my years working for the Baker Administration. In a time of extreme partisanship at the federal level, this was one area where public policy, civil discourse, and private enterprise seemed aligned and sufficiently motivated to find a solution. What we learned, however, is that dollars and access only go so far in combatting a disease that knows no so specific demographic. Instead, it's apparent that a battery of tools is needed to combat and prevent addiction--ranging from strong safety nets, to novel non-addictive pain therapies, and better technology. Introducing Marigold Health. Shrenik Jain, Ravi Shah, Tracey Cohen, MD, FASAM and team have built a proprietary NLP-based platform that--most significantly--improves the lives of those suffering from SUD/SMI. One customer we spoke with noted, "We needed a unique treatment intervention that had supportive research, fit into a CMS established model with a recognized service code, and that would provide positive clinical outcomes in an efficacious and fiscally responsible manner”. Another plainly said: "Marigold is our best hope to reach into the lives and help those who many have already given up on." Honored to join Bill Evans, Sean Day, and the entire syndicate in doing our part to scale a tool we believe will become essential in the fight against addiction. Marigold Health Innospark Ventures Rock Health KdT Ventures Matt Fates Lily Zarrella Venkat Srinivasan
501 Comment -
David Van Sickle
According to the latest report from Rock Health, digital health funding in Q1 2024 totaled $2.7B across 133 deals, with an average deal size of $20.6M. It doesn’t break out device-related investments, but most medtech founders I meet these days are being forced to chase tiny rounds made up of endless little checks, consuming valuable energy and slowing their progress. The benign neglect of this next generation of diagnostic and therapeutic devices is counterproductive and surprising. Given the crowded virtual care market, for example, I’d expect more such companies would be exploring medtech partnerships, investments or acquisitions that'd enable them to back integrate into delivering sharper, and more differentiated, care and treatment. This is exactly what Maverix Medical is doing from the other direction: Reshaping the entire spectrum of lung cancer care by integrating more advanced + effective approaches to screening and diagnosis, treatment and therapeutics, and even palliative care…And putting it all to work through an innovative provider network. One notable investor exception is Y Combinator partner Surbhi Sarna who’s been backing great teams like Selera Medical (YC W24) doing foundational work on ambitious medical devices. Without more support from investors like her, we’re going to increasingly find ourselves stuck with the incremental portfolio improvements from the incumbents, and that’s just not nearly enough.
585 Comments -
Paul Hsu
Coming soon on Aug 1: "Transformation to a Fresh Tomorrow." This is theme of our 3rd Annual Web3 Investor Day, as we welcome the innovators and investors convening in Chicago for these discussions around the next generation Internet. Our theme reflects the optimism, determination and commitment investors and innovators have solidified off the depths of the bear markets to drive success in the bull markets. Broader investor optimism suggests that fresh institutional funds into Web3 across both tokens and equity may endure. Across adoption metrics, customer interest and developer activity, Web3 seems to have normalized. It’s refreshing to see the transformation and next evolution of Web3 and it’s refreshing to meet many of you on August 1. And yet, even with the improved optimism from last year, there still remain open questions in the development and adoption of our next generation Internet: 1. the balance of speculative versus productive investor capital in this current cycle 2. the productive role of liquid trading capital in fostering Web3 innovation 3. the attractiveness of venture investments in follow on financings 4. the role of policy and regulation that may enhance innovation 5. the continued developer activity to improve the underlying infrastructure 6. other Web3 recovery characteristics in target customer use cases. We remain committed to navigating regulatory shifts, fostering investor optimism, and building the customer use cases for Web3. Physical spaces enhance our innovation conversations. In person relationships foster our collaboration. Relationships drive breakthrough innovations. Reach out to Rizza Torres at Decasonic if you would like to join us! #web3investorday #web3 #venturecapital
206 Comments -
Jeff Becker
The hidden years of inception stage. Founders & LP’s rarely understand that the journey of building a great company can involve up to three years of work before an early stage VC will get involved. h/t Peter Walker for the years from incorporation data from Carta https://lnkd.in/e5fFkvDt #vc #founders #investing Antler
8312 Comments -
Kevin Spain
Despite the headwinds many software companies (even public ones) are facing today, there are still those that are delivering great results. Check out how the top decile companies in our Beyond Benchmarks survey are performing. And don't forget to review the full report for many more insights on the state of private software businesses.
22
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More